Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 07, 2015 3:46pm
322 Views
Post# 23500524

RE:RE:RE:RVX Valuation

RE:RE:RE:RVX ValuationHi bfw. Good points.

However, I don't understand your point in the second last paragraph. Unless I misunderstood the $30,000,000 LOC extension by KD is there to fund BETonMACE and IMHO is not an issue at all.

In additon, the cost of this trial is dramatically reduced from Don's original phase 2/3 trial proposal presented in October of 2014. In my previous post I said $25,000,000 to be conservative but I actually think BETonMACE may be under $20,000,000. The information is available but I just don't have time to go back and check it. Hopefully other posters can confirm or straighten me out.

There is also the possibility that BETonMACE, which is a progressive (not the right word but it's what I remember) trial it could end early because if the RRR at various measurement periods is really high (e.g. 70% plus like the post hoc) then it could become statistically significant early in the trial and this could bring up the obvious ethical issue.

Please correct me if I'm wrong but I am absolutely convinced that BETonMACE is fully funded by the LOC.

Cheers and have a great weekend. I buried in wonderful snow in Muskoka.
Toinv  :)

Bullboard Posts